NDMA asks FDA to extend ephedrine comment period to evaluate effect on pseudoephedrine.
This article was originally published in The Tan Sheet
Executive Summary
NDMA SEEKS EXTENSION OF COMMENT PERIOD ON FDA's EPHEDRINE PROPOSAL to prohibit over-the-counter sale of the ingredient and its salts and analogs ("The Tan Sheet" July 31, p. 1). "There are no exigent circumstances to justify adherence" to the thirty-day comment period provided in FDA's July 27 proposal, the Nonprescription Drug Manufacturers Association said in an Aug. 4 letter to the agency. NDMA asked FDA to extend the comment period from Aug. 28 to Oct. 27.